Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines

Journal of Neuroimmunology

Volumn 268, Issue 1-2, 2014, Pages 50-57

  Davtyan, Hayk ^a   Ghochikyan, Anahit ^a   Hovakimyan, Armine ^a   Petrushina, Irina ^b   Yu, Jianmei ^c   Flyer, David ^c,f   Madsen, Peter Juul ^d   Pedersen, Lars Ostergaard ^d   Cribbs, David H ^b,e   Agadjanyan, Michael G ^a,b  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Intercell USA   (United States)

^d H LUNDBECK A S   (Denmark)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NOVAVAX INC   (United States)

Author keywords

Alzheimer's disease; Epitope vaccine; Immune responses; Immunostimulatory patch

Indexed keywords

ALZHEIMER DISEASE VACCINE; DEPVAC; DNA VACCINE; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN ADJUVANT LADEN IMMUNOSTIMULATORY PATCH; LU AF 20513; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PLACEBO; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ALZHEIMER'S DISEASE; EPITOPE VACCINE; IMMUNE RESPONSES; IMMUNOSTIMULATORY PATCH;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; TRANSDERMAL PATCH; VACCINATION; VACCINES, DNA;

EID: 84896736114     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.01.002     Document Type: Article

References (44)

1. Agadjanyan M.G., Trivedi N.N., Kudchodkar S., Bennett M., Levine W., Lin A., Boyer J., Levy D., Ugen K.E., Kim J.J., Weiner D.B. An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV. AIDS Res. Hum. Retrovir. 1997, 13:1561-1572.
2. Babiuk L.A., Pontarollo R., Babiuk S., Loehr B., Van Drunen Littel-Van Den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003, 21:649-658.
3. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64:94-101.
4. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. J. Alzheimer Assoc. 2007, 3:186-191.
5. Cribbs D.H., Ghochikyan A., Tran M., Vasilevko V., Petrushina I., Sadzikava N., Kesslak P., Kieber-Emmons T., Cotman C.W., Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 2003, 15:505-514.
6. Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D.H., Agadjanyan M.G., Ghochikyan A. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther. 2010, 17:261-271.
7. Davtyan H., Ghochikyan A., Movsesyan N., Ellefsen B., Petrushina I., Cribbs D.H., Hannaman D., Evans C.F., Agadjanyan M.G. Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses. Neurodegener. Dis. 2012, 10:261-264.
8. Davtyan H., Ghochikyan A., Petrushina I., Hovakimyan A., Davtyan A., Poghosyan A., Marleau A.M., Movsesyan N., Kiyatkin A., Rasool S., Larsen A.K., Madsen P.J., Wegener K.M., Ditlevsen D.K., Cribbs D.H., Pedersen L.O., Agadjanyan M.G. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J. Neurosci. 2013, 33:4923-4934.
9. Ertl H.C., Xiang Z.Q. Genetic immunization. Viral Immunol. 1996, 9:1-9.
10. Evans C.F., Davtyan H., Petrushina I., Hovakimyan A., Davtyan A., Hannaman D., Cribbs D.H., Agadjanyan M.G., Ghochikyan A. Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimers Dement 2013.
11. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
12. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., Okhuysen P.C., Guerrero N.H., Martinez-Sandoval F.G., Melendez-Romero J.H., Jiang Z.D., Asturias E.J., Halpern J., Torres O.R., Hoffman A.S., Villar C.P., Kassem R.N., Flyer D.C., Andersen B.H., Kazempour K., Breisch S.A., Glenn G.M. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008, 371:2019-2025.
13. Fuller D.H., Corb M.M., Barnett S., Steimer K., Haynes J.R. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 1997, 15:924-926.
14. Ghochikyan A., Mkrtichyan M., Petrushina I., Movsesyan N., Karapetyan A., Cribbs D.H., Agadjanyan M.G. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 2006, 24:2275-2282.
15. Ghochikyan A., Davtyan H., Petrushina I., Hovakimyan A., Movsesyan N., Davtyan A., Kiyatkin A., Cribbs D.H., Agadjanyan M.G. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum. Vaccin. Immunother. 2013, 9:1002-1010.
16. Glenn G.M., Scharton-Kersten T., Vassell R., Matyas G.R., Alving C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 1999, 67:1100-1106.
17. Glenn G.M., Kenney R.T., Ellingsworth L.R., Frech S.A., Hammond S.A., Zoeteweij J.P. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2003, 2:253-267.
18. Glenn G.M., Thomas D.N., Poffenberger K.L., Flyer D.C., Ellingsworth L.R., Andersen B.H., Frech S.A. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 2009, 27(Suppl. 6):G60-G66.
19. Gregoriadis G., Saffie R., De Souza J.B. Liposome-mediated DNA vaccination. FEBS Lett. 1997, 402:107-110.
20. Guebre-Xabier M., Hammond S.A., Ellingsworth L.R., Glenn G.M. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J. Virol. 2004, 78:7610-7618.
21. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., Roberts Z.J., Nesterova G.V., Alving C.R., Glenn G.M. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 2002, 70:1874-1880.
22. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
23. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
24. Hedley M.L., Curley J., Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 1998, 4:365-368.
25. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
26. Jones D.H., Corris S., McDonald S., Clegg J.C., Farrar G.H. Poly(dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15:814-817.
27. Kim J.J., Nottingham L.K., Sin J.I., Tsai A., Morrison L., Oh J., Dang K., Hu Y., Kazahaya K., Bennett M., Dentchev T., Wilson D.M., Chalian A.A., Boyer J.D., Agadjanyan M.G., Weiner D.B. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J. Clin. Investig. 1998, 102:1112-1124.
28. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat. Rev. Genet. 2008, 9:776-788.
29. Langley J.M., Sales V., Mcgeer A., Guasparini R., Predy G., Meekison W., Li M., Capellan J., Wang E. A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or=65years of age. Vaccine 2009, 27:5913-5919.
30. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat. Rev. Neurol. 2010, 6:108-119.
31. Luxembourg A., Evans C.F., Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert. Opin. Biol. Ther. 2007, 7:1647-1664.
32. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
33. McCray A.N., Ugen K.E., Muthumani K., Kim J.J., Weiner D.B., Heller R. Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol. Ther. 2006, 14:647-655.
34. Mkrtichyan M., Ghochikyan A., Movsesyan N., Karapetyan A., Begoyan G., Yu J., Glenn G.M., Ross T.M., Agadjanyan M.G., Cribbs D.H. Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol. 2008, 27:19-24.
35. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., Head E., Biragyn A., Cribbs D.H., Agadjanyan M.G. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine- a novel immunotherapeutic strategy. PLoS ONE 2008, 3:e21-e24.
36. Movsesyan N., Davtyan H., Mkrtichyan M., Petrushina I., Tiraturyan T., Ross T.M., Agadjanyan M.G., Ghochikyan A., Cribbs D.H. Low concentrations of anti-Abeta antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. Hum. Gene Ther. 2010, 21:1569-1576.
37. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
38. Patton R.L., Kalback W.M., Esh C.L., Kokjohn T.A., Van Vickle G.D., Luehrs D.C., Kuo Y.M., Lopez J., Brune D., Ferrer I., Masliah E., Newel A.J., Beach T.G., Castano E.M., Roher A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 2006, 169:1048-1063.
39. Petrushina I., Tran M., Sadzikava N., Ghochikyan A., Vasilevko V., Agadjanyan M.G., Cribbs D.H. Importance of IgG2c isotype in the immune response to b-amyloid in APP/Tg mice. Neurosci. Lett. 2003, 338:5-8.
40. Petrushina I., Ghochikyan A., Mktrichyan M., Mamikonyan G., Movsesyan N., Davtyan H., Patel A., Head E., Cribbs D.H., Agadjanyan M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric A{beta} species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
41. Price D.L., Sisodia S.S. Cellular and molecular biology of Alzheimer's disease and animal models. Annu. Rev. Med. 1994, 45:435-446.
42. Scharton-Kersten T., Yu J., Vassell R., O'Hagan D., Alving C.R., Glenn G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 2000, 68:5306-5313.
43. Torres C.A., Iwasaki A., Barber B.H., Robinson H.L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 1997, 158:4529-4532.
44. Walther W., Stein U., Fichtner I., Schlag P.M. Low-volume jet injection for efficient nonviral in vivo gene transfer. Mol. Biotechnol. 2004, 28:121-128.